# A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years

> **NCT05329051** · PHASE2 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- SARS-CoV-2 Infection
- COVID-19

## Interventions

- **BIOLOGICAL:** SCTV01E
- **BIOLOGICAL:** Comirnaty

## Key facts

- **NCT ID:** NCT05329051
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2022-09-01
- **Final completion:** 2023-03-01
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2022-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05329051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05329051, "A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine in Population Aged ≥18 Years". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05329051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*